Cargando…

Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis

BACKGROUND: Baricitinib is a janus kinase (JAK1/JAK2) inhibitor developed for the treatment of patients suffering from rheumatoid arthritis (RA). Treating RA to the target of remission is current common practice. Cost-effectiveness of different treat-to-target (T2T) strategies, especially ones inclu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van De Laar, Celine J, Oude Voshaar, Martijn A H, Fakhouri, Walid K H, Zaremba-Pechmann, Liliana, De Leonardis, Francesco, De La Torre, Inmaculada, Van De Laar, Mart A F J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167259/ https://www.ncbi.nlm.nih.gov/pubmed/32346301 http://dx.doi.org/10.2147/CEOR.S231558

Ejemplares similares

Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
por: ten Klooster, Peter M., et al.
Publicado: (2019)

Real-world comparative effectiveness of bDMARDs and JAK inhibitors in elderly patients with rheumatoid arthritis
por: Temmoku, Jumpei, et al.
Publicado: (2022)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2021)

Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study
por: Voshaar, Marieke, et al.
Publicado: (2016)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study
por: De La Fuente, Fanny, et al.
Publicado: (2022)

Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis
por: Fakhouri, Walid, et al.
Publicado: (2021)

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
por: Gremese, Elisa, et al.
Publicado: (2020)

Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients
por: van de Laar, Celine Johanna, et al.
Publicado: (2022)

Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis: results from the DREAM registry
por: van de Laar, Celine J., et al.
Publicado: (2019)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
por: Coates, Laura C, et al.
Publicado: (2017)

Measurement properties of physical function scales validated for use in patients with rheumatoid arthritis: A systematic review of the literature
por: Oude Voshaar, Martijn AH, et al.
Publicado: (2011)

Call for action: incorporating wellness practices into a holistic management plan for rheumatoid arthritis—going beyond treat to target
por: Taylor, Peter C., et al.
Publicado: (2021)

Healthcare professionals’ perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis
por: Voshaar, M. J. H., et al.
Publicado: (2022)

Dutch translation and cross-cultural adaptation of the PROMIS(® )physical function item bank and cognitive pre-test in Dutch arthritis patients
por: Oude Voshaar, Martijn AH, et al.
Publicado: (2012)

Effects of bDMARDs on quality of life in patients with psoriatic arthritis: meta-analysis
por: Lu, Yuqiong, et al.
Publicado: (2022)

Measuring everyday functional competence using the Rasch assessment of everyday activity limitations (REAL) item bank
por: Oude Voshaar, Martijn A. H., et al.
Publicado: (2017)

Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years
por: Sánchez-Piedra, Carlos, et al.
Publicado: (2021)

Psychometric properties and cross-language equivalence of the revised Bristol Rheumatoid Arthritis Fatigue and the Rheumatoid Arthritis Impact of Disease scales in rheumatoid arthritis
por: Oude Voshaar, Martijn A. H., et al.
Publicado: (2019)

Molecular mechanisms of resistance to disease modifying antirheumatic drugs (DMARDs)
por: Jansen, G, et al.
Publicado: (2002)

Risk of infection in postmenopausal women with rheumatoid arthritis and osteoporosis taking denosumab and bDMARDS
por: Mirzaei, Alireza, et al.
Publicado: (2021)

bDMARDs retention rate in the biosimilar era: A real-life monocentric study
por: Becciolini, Andrea, et al.
Publicado: (2021)

Efficacy of JAK Inhibitors versus DMARDs in the Treatment of Polymyalgia Rheumatica in China
por: Gu, Juanfang, et al.
Publicado: (2023)

Development and preliminary evaluation of a short self-report measure of generalized pain hypersensitivity
por: van Bemmel, Peter F, et al.
Publicado: (2019)

bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search
por: Verhoef, Lise M., et al.
Publicado: (2017)

Development and validation of a patient-reported gout attack intensity score for use in gout clinical studies
por: Janssen, Carly A, et al.
Publicado: (2019)

Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients
por: Janssen, Carly A., et al.
Publicado: (2017)

Machine learning-based prediction model for responses of bDMARDs in patients with rheumatoid arthritis and ankylosing spondylitis
por: Lee, Seulkee, et al.
Publicado: (2021)

Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry
por: Prior-Español, A., et al.
Publicado: (2021)

Stopping bDMARDs at the beginning of pregnancy is associated with disease flares and preterm delivery in women with rheumatoid arthritis
por: Gerardi, Maria Chiara, et al.
Publicado: (2022)

The impact of bDMARDs on postoperative complications in patients with rheumatoid arthritis: A systematic review and meta-analysis
por: Suto, Takahito, et al.
Publicado: (2023)

Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study
por: Jeong, Seogsong, et al.
Publicado: (2022)

Impact of access to treatment on patient‐reported outcomes among rheumatoid arthritis patients with tDMARDs and bDMARDS in two Latin‐American countries: A prospective observational study
por: Reyes, Juan M., et al.
Publicado: (2023)

The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccination
por: Tobudic, Selma, et al.
Publicado: (2023)

Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis
por: Akter, Ripa, et al.
Publicado: (2020)

Frequency and trends of disease‐modifying antirheumatic drug (DMARD) use in Germany
por: Fassmer, Alexander M., et al.
Publicado: (2016)

Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents
por: Infante, Marco, et al.
Publicado: (2022)

JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy
por: Gremese, Elisa, et al.
Publicado: (2019)

Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
por: Cho, Soo-Kyung, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gs23vbfq9am76nl17nn9d7p9dh